{"name":"NeuroTherapia, Inc.","slug":"neurotherapia-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxQOUFta0hIeVhQWFNUMFZKNzNFWk5WMUxQWDJrbWRxc2ZheERSbE9BSEVnZzFzdFIzbnAtbVJxemZqSlFWMWRva1E4WllISWtaNUw4MThUUFB5SXVyd0dfN0ZXU3IyOC0wejhacG15UllaRFhsaWRpeno4SXNra29FQU1ybkM2cjJzVDh0ZWQ5U3lUS21icmd1bkhMSnpESXQ4U3dfaTNYU1lUMkk2czJ3d3RTUnZHdFVCMGRjclg2YnV1ZVNGWVJ6WEZXVVlxdjFxMUYyTF9sN3hBODk4Q0MzSmhBM044TzdWUGdNdA?oc=5","date":"2026-04-07","type":"trial","source":"PR Newswire","summary":"NeuroTherapia announces completion of its Phase 2a Trial of a novel treatment for Alzheimer's Disease - PR Newswire","headline":"NeuroTherapia announces completion of its Phase 2a Trial of a novel treatment for Alzheimer's Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxPeUx4N1VxLVVxc28zWUFqN2xxa0gwU2xfY2FldkpYcDBDNmFxR2V0azFwVXhGN0dNZFJTd3ZXVzU4cHYtbzZHUmNxVUhKandmdlhuOXM1UHRPbTV6VUs0NEt3WnlSYkZib2JaYTcwM1dOTmlSRzJId0E4bXF1M1FCcmJ6QzFQQ0VtZFVkWGN5aGM0X0FmY1RtQWEzZlNqWWtFQ0pmUHZvNU9SV3Q5LUdiekNaZmo0U2xZNkROM2lMQ05MM1REWkMtLUlYVDg3a29idE4zU3NPekFLRHJUeTZNRzhSSFkzQUhfV0VVbWRTcEtFclpHcUxVYXdXT2JINkhubFBNSzlJSldFMHEyLTliclQwTGpyVlNEWG5XRzdR?oc=5","date":"2025-08-12","type":"trial","source":"globenewswire.com","summary":"Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+ - globenewswire.com","headline":"Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPaENFYUtFRExNVkw4MTg1cGVVaXJJd3I0YWcwaEZmMEZsS25IV1VSc2RBR1JqRTVnOGZaVDI4cHlkc2NLaVpMaEl0MksyNTA2Tkc4Tk5KMkJlQ3pnUWlsMzRRUjRCQlAzbjBSUHVSWjNSMFEwYjZZanh0RFp1MUxYR05vVGdMbFU0V0VGNUh6UGl4Mzg?oc=5","date":"2025-07-10","type":"trial","source":"Yahoo Finance","summary":"Cannabinoid Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Yahoo Finance","headline":"Cannabinoid Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therape","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQYzRIUTc2dFNHWVBsdXFMcXhIMWFfS25uZjk2YVNad19FUjVhdjlkd003MDBfZXhmQ1VYT2JBM3ozZFBtOGZ1dWxTRG84LXNCWV8yMnptTXNPNDlKZEV0NzBLMmhJYmNlc0JTLVNhSGtqQ190YmVpaFF4X0FOcG5aRWxQMFE0QzZNZlFSQXJicExNaWZOd0JrRGJTaEdKRThSNGdhbE5YV2dfUEVTMndObm41SnJSVWgxR1R5M0tFWTNLM2syQVE?oc=5","date":"2024-08-06","type":"pipeline","source":"PR Newswire","summary":"NeuroTherapia Raises $12.3M in the First Close of its Series B Financing - PR Newswire","headline":"NeuroTherapia Raises $12.3M in the First Close of its Series B Financing","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}